Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

Open access
Freedman, Rachel A., Gelman, Rebecca S., Wefel, Jeffrey S., Melisko, Michelle E., Hess, Kenneth R., Connolly, Roisin M., Van Poznak, Catherine H., Niravath, Polly A., Puhalla, Shannon L., Ibrahim, Nuhad, Blackwell, Kimberly L., Moy, Beverly, Herold, Christina, Liu, Minetta C., Lowe, Alarice, Agar, Nathalie Y.R., Ryabin, Nicole, Farooq, Sarah, Lawler, Elizabeth, Rimawi, Mothaffar F., Krop, Ian E., Wolff, Antonio C., Winer, Eric P., Lin, Nancy U. · 2016 · Journal of Clinical Oncology

Abstract

Purpose: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer in the CNS are limited. Neratinib is an irreversible inhibitor of erbB1, HER2, and erbB4, with promising activity in HER2-positive breast cancer; however, its activity in the CNS is unknown. We evaluated the efficacy of treatment with neratinib in patients with HER2-positive breast cancer brain metastases in a multicenter, phase II open-label trial. Patients and Methods: Eligible patients were those with HER2-positive brain metastases (≥ 1 cm in longest dimension) who experienced progression in the CNS after one or more line of CNS-directed therapy, such as whole-brain radiotherapy, stereotactic radiosurgery, and/or surgical resection. Patients received neratinib 240 mg orally once per day, and tumors were assessed every two cycles. The primary endpoint was composite CNS objective response rate (ORR), requiring all of the following: ≥50% reduction in volumetric sum of target CNS lesions and no progression of non-target lesions, new lesions, escalating corticosteroids, progressive neurologic signs/symptoms, or non-CNS progression—the threshold for success was five of 40 responders. Results: Forty patients were enrolled between February 2012 and June 2013; 78% of patients had previous whole-brain radiotherapy. Three women achieved a partial response (CNS objective response rate, 8%; 95% CI, 2% to 22%). The median number of cycles received was two (range, one to seven cycles), with a median progression-free survival of 1.9 months. Five women received six or more cycles. The most common grade ≥ 3 event was diarrhea (occurring in 21% of patients taking prespecified loperamide prophylaxis and 28% of those without prophylaxis). Patients in the study experienced a decreased quality of life over time. Conclusion: Although neratinib had low activity and did not meet our threshold for success, 12.5% of patients received six or more cycles. Studies combining neratinib with chemotherapy in patients with CNS disease are ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.0343

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 171

Metadata

Authors
Freedman, R. A., Gelman, R. S., Wefel, J. S., Melisko, M. E., Hess, K. R., Connolly, R. M., Van Poznak, C. H., Niravath, P. A., Puhalla, S. L., Ibrahim, N., Blackwell, K. L., Moy, B., Herold, C., Liu, M. C., Lowe, A., Agar, N. Y. R., Ryabin, N., Farooq, S., Lawler, E., Rimawi, M. F., Krop, I. E., Wolff, A. C., Winer, E. P., & Lin, N. U.
Venue
Journal of Clinical Oncology
Published
2016-03-20
Volume
34
Issue
9
Pages
945-952
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2263556989
Cited by
171
References
4
FWCI
23.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases. https://app.cochat.ai/papers/10.1200/jco.2015.63.0343
The paper
Freedman, R. A., Gelman, R. S., Wefel, J. S., Melisko, M. E., Hess, K. R., Connolly, R. M., Van Poznak, C. H., Niravath, P. A., Puhalla, S. L., Ibrahim, N., Blackwell, K. L., Moy, B., Herold, C., Liu, M. C., Lowe, A., Agar, N. Y. R., Ryabin, N., Farooq, S., Lawler, E., . . . Lin, N. U. (2016). Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.63.0343

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.